Drug Trial Radar · NCT07162116
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jul 6, 2025
Primary completion
Dec 1, 2025
Study completion May 2026
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be discharged.
Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
XY0206Drug
12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
Moxifloxacin (400 mg)Drug
400mg,On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach
XY0206 PlaceboOther
12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- QT/QTcTime frame: 48 hours after drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PKUCare Luzhong Hospital
Zibo, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.